Office of Commercialization and Economic Development
Office of Technology Commercialization

Repurposing Dabuzalgron to Prevent and Treat Cardiomyopathy and Heart Failure

Technology #15-0105

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Brian Jensen
Managed By
Kelly Parsons
Associate Director, Technology Commercialization 919.962.6277
Patent Protection
US Patent Pending 2019-0117623

Dr. Paul Simpson Jr. at University of California, San Francisco and Dr. Brain C Jensen at University of North Carolina - Chapel Hill have identified and developed a new indication for dabuzalgron: prevention and treatment of cardiomyopathy and heart failure. Dabuzalgron is an alpha-1A- adrenergic receptor agonist that can stimulate smooth muscle contraction in higher doses; however, in this invention, the drug is used at doses below those found to have an effect on smooth muscle contraction and blood pressure. These researchers have shown that dabuzalgron leads to a variety of beneficial intracellular processes in heart muscle cells, including mechanisms that protect the cell from injury or death. Dabuzalgron also could be used to protect the heart from cancer-induced cardiomyopathy.

This new treatment improves upon current cardiomyopathy and heart failure drugs in several ways, including:
 -Does not cause low blood pressure, a common side effect of currently available drugs
- Prevents heart muscle cell death and repairs injury
Additionally, this drug is attractive to develop for heart disease as it is:
 - Administered in a quantity that is measurable in the blood, which is clinically useful
- Has completed pharmacokinetic and toxicology studies
- Already tested in humans for a genitourinary indication


Related Publications: